Alexion Pharmaceuticals (ALXN)
US Market

Alexion Pharmaceuticals Stock Forecast & Price Target

See the Price Targets and Ratings of:

Analyst Rating Consensus

1 Buy
6 Hold
0 Sell
Based on 7 analysts giving stock ratings to
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALXN Stock Price Prediction

Average Price Target

Based on 7 Wall Street analysts offering 12 month price targets for Alexion Pharmaceuticals in the last 3 months. The average price target is $183.60 with a high forecast of $205.00 and a low forecast of $173.00. The average price target represents a change from the last price of .
Highest Price Target$205.00Average Price Target$183.60Lowest Price Target$173.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Upside / Downside
Upgrade Banner
Truist Financial
Alexion (ALXN) downgraded to Hold from Buy at TruistTruist analyst Robyn Karnauskas downgraded Alexion (ALXN) to Hold from Buy with a higher price target of $175, up from $155, after the company agreed to be acquired by AstraZeneca (AZN). The analyst notes that the $175 take-out price is a "very good deal" for AstraZeneca, adding that though she cannot rule out more bidders coming in, she does not see the deal as "hostile" as it is supported by both Boards and expected to go through.
RBC Capital
Alexion Pharmaceuticals (ALXN) PT Raised to $175 at RBC CapitalRBC Capital analyst Kennen MacKay raised the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $175.00 (from $139.00) while maintaining a Outperform rating.
Citi sees Alexion (ALXN) fair value at $214 per share, says bid undervalues company06:4112/14/2012/1406:4112/14/2006:41Citi sees Alexion (ALXN) fair value at $214 per share, says bid undervalues company
AstraZenecas $39 Billion Takeout of Alexion Wins Tepid Wall Street ApprovalGuggenheims Yatin Suneja has rated Alexion at Neutral. Soliris brings in over 80% of the $6 billion in revenue that Suneja expects for Alexion this year. As patents on the antibody product expire, biosimilars could start competing on price. Meanwhile, a bunch of rivals are developing complement treatments of their own, including Johnson Johnson (JNJ) and arGENx (ARGX).
Morgan Stanley
Morgan Stanley Sticks to Its Hold Rating for Alexion Pharmaceuticals (ALXN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AGLagilon health
SHCSotera Health
TSHATaysha Gene Therapies
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

ALXN Stock Forecast FAQ

What is ALXN’s average 12-month price target, according to analysts?
Based on analyst ratings, Alexion Pharmaceuticals’s 12-month average price target is $183.60.
    What is ALXN’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for ALXN, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is ALXN a Buy, Sell or Hold?
        Alexion Pharmaceuticals has a conensus rating of Hold which is based on 1 buy ratings, 6 hold ratings and 0 sell ratings.
          What is Alexion Pharmaceuticals’s price target?
          The average price target for Alexion Pharmaceuticals is $183.60. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $205.00 ,the lowest forecast is $173.00. The average price target represents N/A Increase from the current price of N/A.
            What do analysts say about Alexion Pharmaceuticals?
            Alexion Pharmaceuticals’s analyst rating consensus is a ‘Hold. This is based on the ratings of 7 Wall Streets Analysts.

              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis